NASDAQ:CLRB 5 May 2026

Cellectar Biosciences Stock: $140 Million Deal Puts Iopofosine FDA Filing in Focus

Cellectar Biosciences secured up to $140 million in new financing and reported a 83.6% overall response rate for iopofosine I 131 in a Phase 2b study for Waldenström macroglobulinemia. The company’s cash had fallen to $13.2 million at the end of 2025, raising doubts about its ability to continue. Shares traded heavily, with volume surging to 53.78 million. Cellectar plans a confirmatory trial and possible FDA filing.

5 May 2026

NASDAQ:CLRB·Stock Market

U.S. Stock Futures Fall Amid Iran Strikes and Inflation Concerns
June 10, 2026, 9:04 AM EDT. Nasdaq futures declined over 1% as former President Donald Trump warned of further actions against Iran following recent strikes. Investors also braced for upcoming Consumer Price Index (CPI) data, with economists forecasting inflation to surpass a critical threshold. The developments heightened market jitters, impacting investor sentiment ahead of key economic releases.

BlackBerry Drops Again; QNX Gains on the Line With June Earnings Ahead

10 June 2026

BlackBerry shares dropped 4.84% to $8.84 Tuesday and slid further to $8.42 premarket Wednesday, erasing part of a 49% rally as investors question whether QNX and Secure Communications growth can justify recent gains ahead of Q1 fiscal 2027 earnings on June 25; the stock is now down 14.5% from last week’s close.

TSMC Shares Slip After Reporting Record May Sales, AI Strains Still in Focus

10 June 2026

TSMC posted record May revenue of NT$416.98 billion, up 30.1% year-on-year, but shares fell 2.17% as investors worry whether TSMC can meet soaring AI chip demand without straining capacity or margins; U.S. ADRs also dropped in premarket trading, reflecting market concerns despite the sales surge.

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

10 June 2026

Nuvalent soared 39.28% to $123.25 after GSK agreed to buy the company for $124 per share in cash, leaving a narrow 0.6% spread as investors shift focus to the $10.6 billion merger’s tender-offer timing, antitrust review, and FDA decision dates for two lung-cancer drugs in September and November 2026.

Wellchange Holdings Shares Pop Premarket as Traders Look at Share Count, AI Angle

10 June 2026

Wellchange Holdings (NASDAQ: WCT) soared 27.5% to $1.67 in premarket trading despite no new company news, as traders drove volume to 25.91 million shares; the Hong Kong software firm’s 2025 revenue fell 41.6% to $1.35 million with a $7.32 million net loss, and its AI platform launch remains pending.

AT&T trades near $22.71 while CFO pushes back on SpaceX challenge to fiber

10 June 2026

AT&T reaffirmed its 2026 outlook and a $4.0–$4.5 billion Q2 free-cash-flow target at the Mizuho conference, keeping shares steady at $22.71 as investors weigh management’s confidence against rising competitive risk from SpaceX’s Starlink and Amazon Leo satellite broadband.

NASDAQ:CLRB 5 May 2026

Cellectar Biosciences Stock: $140 Million Deal Puts Iopofosine FDA Filing in Focus

Stock Market Today

Latest articles

BlackBerry Drops Again; QNX Gains on the Line With June Earnings Ahead

TSMC Shares Slip After Reporting Record May Sales, AI Strains Still in Focus

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Wellchange Holdings Shares Pop Premarket as Traders Look at Share Count, AI Angle

AT&T trades near $22.71 while CFO pushes back on SpaceX challenge to fiber